AAUM (Average Assets Under Management) of ₹207.44 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 77.8% | 78.9% | ▲ +1.1% |
| Healthcare Services | 21.3% | 20.3% | ▼ -1.0% |
| Healthcare Equipment & Supplies | 1.0% | 1.0% | ● +0.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 78.9% | 79.9% | ▲ +1.0% |
| Healthcare Services | 20.3% | 19.3% | ▼ -1.0% |
| Healthcare Equipment & Supplies | 1.0% | 1.0% | ● 0.0% |
Comparing Aug 2026 → Sep 2026
| # | Stock | Sector | Weight (Sep 2026) |
|---|---|---|---|
| 1 | Anthem Biosciences Limited ₹3.14 Cr |
Pharmaceuticals & Biotechnology | 1.42% |
| # | Stock | Sector | Last Weight (Aug 2026) |
|---|---|---|---|
| 1 | Pfizer Limited ₹2.34 Cr |
Pharmaceuticals & Biotechnology | 1.07% |
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Laurus Labs Limited ₹26.12 Cr |
Pharmaceuticals & Biotechnology | 11.22% | 11.84% | +0.62% |
| 2 | Wockhardt Limited ₹5.92 Cr |
Pharmaceuticals & Biotechnology | 2.34% | 2.68% | +0.34% |
| 3 | Ajanta Pharma Limited ₹5.59 Cr |
Pharmaceuticals & Biotechnology | 2.29% | 2.53% | +0.24% |
| 4 | Mankind Pharma Limited ₹9.61 Cr |
Pharmaceuticals & Biotechnology | 4.13% | 4.36% | +0.23% |
| 5 | Sai Life Sciences Limited ₹7.14 Cr |
Pharmaceuticals & Biotechnology | 3.03% | 3.24% | +0.21% |
| 6 | Abbott India Limited ₹4.79 Cr |
Pharmaceuticals & Biotechnology | 2.03% | 2.17% | +0.14% |
| 7 | Acutaas Chemicals Ltd ₹5.76 Cr |
Pharmaceuticals & Biotechnology | 2.47% | 2.61% | +0.14% |
| 8 | Krishna Institute Of Medical Sciences Limited ₹6.75 Cr |
Healthcare Services | 2.95% | 3.06% | +0.11% |
| 9 | Dr. Lal Path Labs Limited ₹5.25 Cr |
Healthcare Services | 2.27% | 2.38% | +0.11% |
| 10 | Granules India Limited ₹4.23 Cr |
Pharmaceuticals & Biotechnology | 1.81% | 1.92% | +0.11% |
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Fortis Healthcare Limited ₹13.59 Cr |
Healthcare Services | 7.12% | 6.16% | -0.96% |
| 2 | Biocon Limited ₹8.74 Cr |
Pharmaceuticals & Biotechnology | 4.43% | 3.96% | -0.47% |
| 3 | Lupin Limited ₹16.70 Cr |
Pharmaceuticals & Biotechnology | 8.01% | 7.57% | -0.44% |
| 4 | Glenmark Pharmaceuticals Limited ₹11.91 Cr |
Pharmaceuticals & Biotechnology | 5.62% | 5.40% | -0.22% |
| 5 | Neuland Laboratories Limited ₹6.24 Cr |
Pharmaceuticals & Biotechnology | 2.99% | 2.83% | -0.16% |
| 6 | GlaxoSmithKline Pharmaceuticals Limited ₹3.88 Cr |
Pharmaceuticals & Biotechnology | 1.90% | 1.76% | -0.14% |
| 7 | Syngene International Limited ₹2.35 Cr |
Healthcare Services | 1.15% | 1.06% | -0.09% |
| 8 | Narayana Hrudayalaya Limited ₹4.19 Cr |
Healthcare Services | 1.98% | 1.90% | -0.08% |
| 9 | Aurobindo Pharma Limited ₹15.65 Cr |
Pharmaceuticals & Biotechnology | 7.16% | 7.09% | -0.07% |
| 10 | Global Health Limited ₹4.10 Cr |
Healthcare Services | 1.91% | 1.86% | -0.05% |
30 stocks — Sep 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹26.12 Cr |
Pharmaceuticals & Biotechnology |
11.84%
|
|
| 2 |
₹16.70 Cr |
Pharmaceuticals & Biotechnology |
7.57%
|
|
| 3 |
₹15.65 Cr |
Pharmaceuticals & Biotechnology |
7.09%
|
|
| 4 |
₹13.59 Cr |
Healthcare Services |
6.16%
|
|
| 5 |
₹11.91 Cr |
Pharmaceuticals & Biotechnology |
5.40%
|
|
| 6 |
₹10.55 Cr |
Pharmaceuticals & Biotechnology |
4.78%
|
|
| 7 |
₹9.61 Cr |
Pharmaceuticals & Biotechnology |
4.36%
|
|
| 8 |
₹9.07 Cr |
Pharmaceuticals & Biotechnology |
4.11%
|
|
| 9 |
₹8.74 Cr |
Pharmaceuticals & Biotechnology |
3.96%
|
|
| 10 |
₹7.83 Cr |
Pharmaceuticals & Biotechnology |
3.55%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.